Originally published as JCO Early Release 10.1200/JCO.2005.12.072 on April 18 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schöder, H. Articles by Yeung, H. W.D. Search for Related Content PubMed PubMed Citation Articles by Schöder, H. Articles by Yeung, H. W.D. Related Articles Related Editorial

Intensity of ¹⁸Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s Lymphoma

From the Department of Radiology, Nuclear Medicine Service; Department of Medicine, Lymphoma Service; and Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY

Address reprint requests to Heiko Schöder, MD, Memorial Sloan-Kettering Cancer Center, Department of Radiology, Nuclear Medicine Service, Box 77, 1275 York Avenue, New York, NY 10021; e-mail: schoderh{at}mskcc.org

PURPOSE: ¹⁸Fluorodeoxyglucose positron emission tomography (FDG PET) is widely used for the staging of lymphoma. We investigated whether the intensity of tumor FDG uptake could differentiate between indolent and aggressive disease.

MATERIALS AND METHODS: PET studies of 97 patients with non-Hodgkin's lymphoma who were untreated or had relapsed and/or persistent disease and had not received treatment within the last 6 months were analyzed, and the highest standardized uptake value (SUV) per study was recorded. Correlations were made with histopathology.

RESULTS: FDG uptake was lower in indolent than in aggressive lymphoma for patients with new (SUV, 7.0 ± 3.1 v 19.6 ± 9.3; P < .01) and relapsed (SUV, 6.3 ± 2.7 v 18.1 ± 10.9; P = .04) disease. Despite overlap between indolent and aggressive disease in the low SUV range (indolent, 2.3 to 13.0; aggressive, 3.2 to 43.0), all cases of indolent lymphoma had an SUV 13. A receiver operating characteristic (ROC) analysis demonstrated that the SUV distinguished reasonably well between aggressive and indolent disease (area under ROC curve, 84.7%), and an SUV > 10 excluded indolent lymphoma with a specificity of 81%. With a higher cutoff for the SUV, the specificity would have been higher.

CONCLUSION: FDG uptake is lower in indolent than in aggressive lymphoma. Patients with NHL and SUV > 10 have a high likelihood for aggressive disease. This information may be helpful if there is discordance between biopsy and clinical behavior.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Related Editorial

• Role of Positron Emission Tomography in Lymphoma
  Malik E. Juweid and Bruce D. Cheson
  JCO 2005 23: 4577-4580 [Full Text]

This article has been cited by other articles:

				N. A. Mohile, L. M. DeAngelis, and L. E. Abrey The utility of body FDG PET in staging primary central nervous system lymphoma Neuro-oncol, April 1, 2008; 10(2): 223 - 228. [Abstract] [Full Text] [PDF]

				C. Bodet-Milin, F. Kraeber-Bodere, P. Moreau, L. Campion, B. Dupas, and S. Le Gouill Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma Haematologica, March 1, 2008; 93(3): 471 - 472. [Abstract] [Full Text] [PDF]

				P. Seam, M. E. Juweid, and B. D. Cheson The role of FDG-PET scans in patients with lymphoma Blood, November 15, 2007; 110(10): 3507 - 3516. [Abstract] [Full Text] [PDF]

				S. Kako, K. Izutsu, Y. Ota, Y. Minatani, M. Sugaya, T. Momose, K. Ohtomo, Y. Kanda, S. Chiba, T. Motokura, et al. FDG-PET in T-cell and NK-cell neoplasms Ann. Onc., October 1, 2007; 18(10): 1685 - 1690. [Abstract] [Full Text] [PDF]

				C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani, J. Dupuis, G. Paone, J.-N. Talbot, A. Rahmouni, and M. Meignan Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis J. Nucl. Med., October 1, 2007; 48(10): 1626 - 1632. [Abstract] [Full Text] [PDF]

				M. E. Juweid, S. Stroobants, O. S. Hoekstra, F. M. Mottaghy, M. Dietlein, A. Guermazi, G. A. Wiseman, L. Kostakoglu, K. Scheidhauer, A. Buck, et al. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J. Clin. Oncol., February 10, 2007; 25(5): 571 - 578. [Abstract] [Full Text] [PDF]

				A. K. Buck, M. Bommer, S. Stilgenbauer, M. Juweid, G. Glatting, H. Schirrmeister, T. Mattfeldt, D. Tepsic, D. Bunjes, F. M. Mottaghy, et al. Molecular Imaging of Proliferation in Malignant Lymphoma. Cancer Res., November 15, 2006; 66(22): 11055 - 11061. [Abstract] [Full Text] [PDF]

				Y. S. Jhanwar and D. J. Straus The Role of PET in Lymphoma J. Nucl. Med., August 1, 2006; 47(8): 1326 - 1334. [Abstract] [Full Text] [PDF]

				S. M. Larson and L. H. Schwartz 18F-FDG PET as a Candidate for "Qualified Biomarker": Functional Assessment of Treatment Response in Oncology J. Nucl. Med., June 1, 2006; 47(6): 901 - 903. [Full Text] [PDF]

				S. Wohrer, U. Jaeger, K. Kletter, A. Becherer, A. Hauswirth, K. Turetschek, M. Raderer, and M. Hoffmann 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading Ann. Onc., May 1, 2006; 17(5): 780 - 784. [Abstract] [Full Text] [PDF]

				M. E. Juweid and B. D. Cheson Role of Positron Emission Tomography in Lymphoma J. Clin. Oncol., July 20, 2005; 23(21): 4577 - 4580. [Full Text] [PDF]